Gene Griffin, D.V.M., M.S.
Gene Griffin is an immunologist with 28 years of drug development experience in pharmaceutical and biotechnology companies including a Danish start-up company.
Formerly, for eight years, he was a Senior Director at Alexion Pharmaceuticals in R&D and Business Development. In this capacity, Gene was instrumental in the expansion of Soliris® (C5 antibody) into additional complement-mediated rare diseases and is a co-inventor on several of the patents. He contributed to the company’s diversification into enzyme replacement therapies (Strensiq® and Kanuma®) and exploration of RNA technologies and gene therapy as therapeutics in rare diseases. Additionally, he fostered and managed business partnerships with companies and academic institutions, including Yale University.
Previously, he worked in multiple disease indications with small molecule and protein therapeutics at Biogen, Bristol-Myers Squibb (BMS), Sandoz, and Parke-Davis in various discovery and development responsibilities. Also, at the Convatec Division of BMS, he helped developed medical devices and is co-inventor for medical use of one device.
Gene earned his Doctor of Veterinary Medicine degree at Tuskegee University and is a member of Phi Zeta Honor Society. He earned his Master and Bachelor of Science degrees from the University of Connecticut. He did his Postdoctoral research in Transplantation-Related Vascular Immunology at the Milton S. Hershey Medical Center, Pennsylvania State University.